相似文献
1
Gynecomastia and antihypertensive therapy.
J Clin Hypertens (Greenwich). 2004 Aug;6(8):469-70. doi: 10.1111/j.1524-6175.2004.3735.x.
2
The effect of low-dose spironolactone on resistant hypertension.
J Am Soc Hypertens. 2010 Nov-Dec;4(6):290-4. doi: 10.1016/j.jash.2010.10.001.
3
Disappearance of spironolactone-induced gynecomastia with triamteren.
Intern Med. 2001 Jun;40(6):550. doi: 10.2169/internalmedicine.40.550.
4
Ga-67 citrate and F-18 FDG uptake in spironolactone-induced gynecomastia.
Clin Nucl Med. 2005 Feb;30(2):105-6. doi: 10.1097/00003072-200502000-00008.
5
[Old man with bosom].
MMW Fortschr Med. 2006 Jun 29;148(26):61.
6
Gynecomastia and hypertension.
J Clin Hypertens (Greenwich). 2005 Apr;7(4):245-8. doi: 10.1111/j.1524-6175.2005.04105.x.
8
[Therapeutic combinations, side effects and interactions of antihypertensive drugs].
Minerva Cardioangiol. 1976 Jun;24(6):456-64.
9
Efficacy of spironolactone therapy in patients with true resistant hypertension.
Hypertension. 2010 Jan;55(1):147-52. doi: 10.1161/HYPERTENSIONAHA.109.140988. Epub 2009 Oct 26.
10
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
BMJ. 2003 Jul 19;327(7407):147-9. doi: 10.1136/bmj.327.7407.147.
引用本文的文献
1
Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review.
Endocrine. 2020 Apr;68(1):6-15. doi: 10.1007/s12020-020-02197-5. Epub 2020 Feb 17.
2
The renin-angiotensin-aldosterone system and its suppression.
J Vet Intern Med. 2019 Mar;33(2):363-382. doi: 10.1111/jvim.15454. Epub 2019 Feb 26.
3
Gynecomastia - Conservative and Surgical Management.
Breast Care (Basel). 2018 Dec;13(6):419-424. doi: 10.1159/000494276. Epub 2018 Nov 14.
4
Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?
Eur J Clin Pharmacol. 2019 Jun;75(6):837-847. doi: 10.1007/s00228-018-02615-8. Epub 2019 Feb 13.
5
The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
Curr Clin Pharmacol. 2019;14(2):78-83. doi: 10.2174/1574884713666181116100946.
6
Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology.
Oxid Med Cell Longev. 2018 Sep 19;2018:1204598. doi: 10.1155/2018/1204598. eCollection 2018.
7
A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.
Medicine (Baltimore). 2017 Dec;96(48):e8719. doi: 10.1097/MD.0000000000008719.
8
Gynecomastia.
Mayo Clin Proc. 2010 Oct;85(10):961-2. doi: 10.4065/mcp.2010.0093.
9
Male gynecomastia.
Mayo Clin Proc. 2009 Aug;84(8):672. doi: 10.4065/84.8.672.
10
Gynecomastia and hypertension.
J Clin Hypertens (Greenwich). 2005 Apr;7(4):245-8. doi: 10.1111/j.1524-6175.2005.04105.x.
本文引用的文献
1
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb.
2
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med. 2003 Apr 3;348(14):1309-21. doi: 10.1056/NEJMoa030207. Epub 2003 Mar 31.
3
Aldosterone blockade and heart failure.
N Engl J Med. 2003 Apr 3;348(14):1380-2. doi: 10.1056/NEJMe030030. Epub 2003 Mar 31.
4
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001.
5
Pathophysiology of spironolactone-induced gynecomastia.
Ann Intern Med. 1977 Oct;87(4):398-403. doi: 10.7326/0003-4819-87-4-398.
Zotero 插件